Aptamer Group plc

Equities

APTA

GB00BNRRP542

Advanced Medical Equipment & Technology

Delayed London S.E. 06:58:08 2024-04-24 am EDT 5-day change 1st Jan Change
0.8735 GBX +20.48% Intraday chart for Aptamer Group plc +66.38% -24.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EARNINGS AND TRADING: Zenova's Kitemark award; Carnival's eyes savings AN
Aptamer inks new Optimer+ transplant rejection therapy partnership AN
Aptamer Group, Kairos Biotech Team Up to Improve Transplant Success MT
Aptamer Group Files Patent Application for Optimer Binders MT
Aptamer submits patent application for Optimer binders AN
EARNINGS AND TRADING: Arbuthnot ups payout as profit more than doubles AN
Aptamer Group plc Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Zentek Says Potential COVID-19 Drug Shows 'Promising' Safety Profile in Preclinical Trial MT
Transcript : Aptamer Group plc - Special Call
Transcript : Aptamer Group plc - Pre Recorded Special Call
Aptamer shares jump on successful Unilever contract progression AN
Aptamer Group, Unilever Prepare to Patent Optimers Developed Under Partnership MT
Aptamer says new Optimer+ delivers improved results AN
Aptamer Group plc Announces R&D Progress on New Optimer®? + Platform CI
Aptamer and Neuro-Bio begin Alzheimer's test development second phase AN
Aptamer Group, Neuro-Bio Enter Second Phase of Partnership for Alzheimer's Flow Test Development MT
Aptamer shares plunge as half-year revenue to fall by 70% AN
Aptamer Group plc Provides Revenue Guidance for the First Half of the Fiscal Year 2024 CI
Zentek Announces "Positive" Therapeutic Results Achieved by Triera Biosciences for C19HBA MT
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research MT
Ribomic Enters Into Drug Research Collaboration with Ajinomoto MT
Aptamer inks deal for Optimer discovery with biotech firm AN
Aptamer Group Signs Optimer Discovery Deal With Genetic Medicines Company MT
Aptamer Group plc Announces Material Agreement with Genetic Medicines Company CI
Zentek Launches Triera, a New Subsidiary, to Commercialize its Aptamer Covid-19 Treatment MT
Chart Aptamer Group plc
More charts
Aptamer Group plc is a developer of Optimer binders in the life sciences industry. It offers custom Optimer selection and development services. It delivers aptamer-based solutions to its customer bases for a range of therapeutic, diagnostic, and target-binding applications. It develops Optimer binders for therapeutics, diagnostics, bioprocessing, and research applications. The Optimer platform delivers aptamer tools that enables researchers and developers across the spectrum of the life sciences. Optimer binders has developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Optimer act as agonists, antagonists, or cell-type-specific targeting moieties for the delivery of therapeutic agents to target cells and tissues in the treatment of disease.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. APTA Stock
  4. News Aptamer Group plc
  5. Aptamer Group Secures Two Contracts for Optimer Binders